- Home
- CTLP vs BCYC Comparison
CTLP vs BCYC Comparison
Compare CTLP & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTLP
- BCYC
- Stock Information
- Founded
- CTLP 1992
- BCYC 2009
- Country
- CTLP United States
- BCYC United Kingdom
- Employees
- CTLP N/A
- BCYC N/A
- Industry
- CTLP EDP Services
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- CTLP Technology
- BCYC Health Care
- Exchange
- CTLP Nasdaq
- BCYC Nasdaq
- Market Cap
- CTLP 642.2M
- BCYC 566.5M
- IPO Year
- CTLP N/A
- BCYC 2019
- Fundamental
- Price
- CTLP $11.03
- BCYC $8.05
- Analyst Decision
- CTLP Hold
- BCYC Buy
- Analyst Count
- CTLP 5
- BCYC 10
- Target Price
- CTLP $11.50
- BCYC $25.00
- AVG Volume (30 Days)
- CTLP 3.1M
- BCYC 297.7K
- Earning Date
- CTLP 05-08-2025
- BCYC 08-05-2025
- Dividend Yield
- CTLP N/A
- BCYC N/A
- EPS Growth
- CTLP 404.65
- BCYC N/A
- EPS
- CTLP 0.80
- BCYC N/A
- Revenue
- CTLP $292,642,000.00
- BCYC $25,722,000.00
- Revenue This Year
- CTLP $15.56
- BCYC $7.35
- Revenue Next Year
- CTLP $14.42
- BCYC N/A
- P/E Ratio
- CTLP $13.79
- BCYC N/A
- Revenue Growth
- CTLP 12.51
- BCYC N/A
- 52 Week Low
- CTLP $5.82
- BCYC $6.10
- 52 Week High
- CTLP $11.36
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- CTLP 72.65
- BCYC 55.72
- Support Level
- CTLP $11.02
- BCYC $7.06
- Resistance Level
- CTLP $11.06
- BCYC $8.12
- Average True Range (ATR)
- CTLP 0.04
- BCYC 0.40
- MACD
- CTLP -0.08
- BCYC 0.12
- Stochastic Oscillator
- CTLP 42.86
- BCYC 95.20
About CTLP Cantaloupe Inc.
Cantaloupe Inc operates in the small ticket electronic payments industry. It provides wireless, cashless, micro-transactions, and networking services within the unattended Point of Sale (POS) market. Its products and services portfolio consists of ePort Cashless devices, eSuds, EnergyMisers, and Value-added services which include Loyalty and Prepaid, Intelligent Vending, and others. The company offers services to different industries covering car wash, taxi and transportation, laundry, vending, kiosk, amusement, and arcade. The company derives revenue from the sale or lease of equipment and services to the small ticket, unattended POS market, and the majority of its revenue is derived from subscription and transaction fees.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.